ArticleWorld journal of cardiology2024
Excess cardiovascular mortality in men with non-alcoholic fatty liver disease: A cause for concern!
Article in World journal of cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Comparative performance of insulin resistance-related indices in predicting adverse cardiovascular events among individuals with NAFLD and MASLD: a multi-center cohort study.Cardiovascular diabetology · 2026Observational
- Article
- Metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction: A state-of-the-art review.World journal of cardiology · 2026Review
- Transient Elastography and Fibroscan: Stethoscope of a Hepatologist in Today's World.Current hepatology reports · 2025Article
- Perturbation of Circulating Inflammatory Proteins Mediates the Relationship Between Cholecystectomy and Nonalcoholic Fatty Liver Disease: A Multivariate and Mediation Mendelian Randomization Study.Health science reports · 2025Article
- Association between urinary albumin-to-creatinine ratio and all-cause and cardiovascular-cause mortality among MASLD: NHANES 2001-2018.Frontiers in nutrition · 2025Article
- Reduced Platelet Aggregation and Plasma Cytokine Levels Mitigate Progressive Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Journal of inflammation research · 2025Article
- Triglyceride-cholesterol-body weight index associated with the risk of metabolic dysfunction-associated steatotic liver disease: a population-based cross-sectional study.Frontiers in nutrition · 2025Article
- GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis.World journal of gastroenterology · 2024Review
- Cardiovascular and nonalcoholic fatty liver disease: Sharing common ground through SIRT1 pathways.World journal of cardiology · 2024Review
- Recent developments in non-invasive methods for assessing metabolic dysfunction-associated fatty liver disease.World journal of gastroenterology · 2024Review
- Addressing the alarming link between nonalcoholic fatty liver disease and cardiovascular mortality in men.World journal of cardiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) has emerged as the commonest cause of chronic liver disease worldwide in recent years. With time, our understanding of NAFLD has evolved from an isolated liver condition to a systemic disease with significant manifestations beyond the liver. Amongst them, cardiovascular diseases (CVDs) are the most important and clinically relevant. Recent research supports a strong independent link between NALFD and CVD beyond the shared risk factors and pathophysiology. Female sex hormones are well known to not only protect against CVD in pre-menopausal females, but also contribute to improved adipose tissue function and preventing its systemic deposition. Recent research highlights the increased risk of major adverse cardiovascular-cerebral events (MACCE) amongst male with NAFLD compared to females. Further, racial variation was observed in MACCE outcomes in NAFLD, with excess mortality in the Native Americans and Asian Pacific Islanders compared to the other races.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.